(0)

Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Ottawa Marriott Hotel

Oct 16, 2017 8:30 AM - Oct 16, 2017 5:00 PM

100 Kent Street , Ottawa, ON K1P5R7 , CANADA

Course 2: ICH Clinical Safety and Efficacy Stream

Overview

Short Course* Registration: 8:00AM-4:30PM

The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use is unique in bringing together the regulatory authorities and pharmaceutical industry to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has gradually evolved to respond to the increasingly global face of drug development. ICH's mission is to achieve greater harmonization worldwide to ensure that safe, effective, and high-quality medicines are developed and registered in the most resource-efficient manner.
Harmonization is achieved through the development of ICH Guidelines via a process of scientific consensus with regulatory and industry experts working side-by-side. The key to the success of this process is the commitment of the ICH regulators to implement the final Guidelines.

This introductory training course will provide an overview of the ICH process, the value that ICH brings to drug regulation in Canada, as well as ICH clinical safety and efficacy guidelines.

View the agenda here!

Featured Topics

  • ICH Introduction
  • Risk Management Planning and E2C: PBRER/PSUR Review in Canada
  • E9: Addendum to Defining Appropriate Estimand for a Clinical Trial/Sensitivity Analyses  
  • M4E(R2): Enhancing the Format and Structure of Benefit-Risk Information in ICH 
  • S9: Nonclinical Evaluation for Anticancer Pharmaceuticals 
  • E15, E16, and E18: Pharmacogenomics  
  • E11: Addendum to Paediatric Drug Development
*Short Courses are not included in the conference registration and require a separate fee.

Return to DIA Annual Canadian Meeting

What you will learn

At the conclusion of this short course, participants should be able to:

  • Understand the ICH process and how ICH guidelines are developed and implemented in Canada
  • Recognize the value that ICH brings to drug regulation in Canada
  • Describe and understand key ICH quality guidelines
  • Recognize how and when to use the guidelines throughout the life cycle of a drug product

Who should attend?

Professionals involved in:

  • Drug safety
  • Pharmacoepidemiology
  • Regulatory affairs
  • Clinical development/clinical sciences
  • Project management

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.